6919 Stock Overview
Caliway Biopharmaceuticals Co.Ltd develops small molecule drugs for medical aesthetic and inflammatory disease.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Caliway Biopharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$377.00 |
| 52 Week High | NT$406.00 |
| 52 Week Low | NT$150.25 |
| Beta | 0 |
| 1 Month Change | 2.86% |
| 3 Month Change | 50.50% |
| 1 Year Change | 141.28% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 482.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6919 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -0.5% | 3.3% | 2.5% |
| 1Y | 141.3% | 6.3% | 29.9% |
Return vs Industry: 6919 exceeded the TW Pharmaceuticals industry which returned 6.3% over the past year.
Return vs Market: 6919 exceeded the TW Market which returned 29.9% over the past year.
Price Volatility
| 6919 volatility | |
|---|---|
| 6919 Average Weekly Movement | 8.7% |
| Pharmaceuticals Industry Average Movement | 4.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in TW Market | 8.5% |
| 10% least volatile stocks in TW Market | 2.3% |
Stable Share Price: 6919's share price has been volatile over the past 3 months.
Volatility Over Time: 6919's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | Yufang Ling | www.caliway.com.tw |
Caliway Biopharmaceuticals Co Ltd develops small molecule drugs for medical aesthetic and inflammatory disease. The company was founded in 2012 and is based in New Taipei City, Taiwan.
Caliway Biopharmaceuticals Co., Ltd. Fundamentals Summary
| 6919 fundamental statistics | |
|---|---|
| Market cap | NT$52.56b |
| Earnings (TTM) | -NT$611.78m |
| Revenue (TTM) | NT$39.20m |
1,341x
P/S Ratio-85.9x
P/E RatioIs 6919 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6919 income statement (TTM) | |
|---|---|
| Revenue | NT$39.20m |
| Cost of Revenue | NT$11.55m |
| Gross Profit | NT$27.65m |
| Other Expenses | NT$639.43m |
| Earnings | -NT$611.78m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.39 |
| Gross Margin | 70.54% |
| Net Profit Margin | -1,560.87% |
| Debt/Equity Ratio | 0% |
How did 6919 perform over the long term?
See historical performance and comparison